Grant recipients who attended the 34th annual European Workshop for Rheumatology Research recall conference highlights, connecting with overseas colleagues
Rheumatology Research Foundation’s Campaign to Advance Patient Care Ahead of Schedule
After three years, the Foundation’s Journey to Cure initiative to recruit and train new rheumatologists has achieved 78% of its $60 million, five-year goal
Why Tweaking Molecular Structures Can Be Hazardous to Our Health
The rise and fall of rofecoxib and valdecoxib demonstrate the need for caution in new drug development
Treg Cells May Orchestrate Muscle Repair after Injury
New research shows the accumulation of regulatory T cells in damaged muscle corresponds with a switch in the myeloid cell infiltrate from a proinflammatory to a proregenerative phenotype.
Rheumatologists on the Move
Awards, appointments and announcements in the world of rheumatology
Rheuminations: Ankylosing Spondylitis Sometimes Defies Detection
How method of diagnosing, treating this inflammatory back disease characterized by stiffness and the presence of HLA-B27 gene has evolved
Rheumatologists Make Progress Defining Spectrum of Axial Spondyloarthritis
New research clarifies terminology used for diagnosis, but questions remain around epidemiology, genetics and management of patients with axial skeletal inflammation
MicroRNA-Based Therapeutics Hold Promise Against Lupus, Other Rheumatic Diseases Note Experts at the ACR/ARHP’s 2013 Annual Meeting
Studies suggest deregulation, dysfunction of miRNAs in human, mice models of lupus may be future targets for gene therapy
Treating Early-Stage Spondyloarthritis May Prevent Disease Progression, Say Researchers at the ACR/ARHP Winter Rheumatology Symposium
Therapy with tumor necrosis factor inhibitors, nonsteroidal antiinflammatory drugs, ustekinumab in early stages of osteitis may halt molecular switching to bone-forming phenotype characteristic of SpA
Rheumatology Research Foundation to Play Role in Developing New RA, Lupus Treatments
Foundation joins Accelerating Medicines Partnership, led by National Institutes of Health, to fast-track viable potential drug therapies for lupus, rheumatoid arthritis
- « Previous Page
- 1
- …
- 44
- 45
- 46
- 47
- 48
- …
- 77
- Next Page »